全文获取类型
收费全文 | 3780篇 |
免费 | 275篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 124篇 |
妇产科学 | 154篇 |
基础医学 | 351篇 |
口腔科学 | 37篇 |
临床医学 | 775篇 |
内科学 | 849篇 |
皮肤病学 | 24篇 |
神经病学 | 235篇 |
特种医学 | 48篇 |
外科学 | 300篇 |
综合类 | 28篇 |
一般理论 | 6篇 |
预防医学 | 587篇 |
眼科学 | 20篇 |
药学 | 207篇 |
中国医学 | 6篇 |
肿瘤学 | 295篇 |
出版年
2023年 | 22篇 |
2022年 | 25篇 |
2021年 | 83篇 |
2020年 | 51篇 |
2019年 | 65篇 |
2018年 | 85篇 |
2017年 | 78篇 |
2016年 | 99篇 |
2015年 | 103篇 |
2014年 | 122篇 |
2013年 | 189篇 |
2012年 | 269篇 |
2011年 | 294篇 |
2010年 | 168篇 |
2009年 | 147篇 |
2008年 | 264篇 |
2007年 | 333篇 |
2006年 | 347篇 |
2005年 | 277篇 |
2004年 | 239篇 |
2003年 | 211篇 |
2002年 | 205篇 |
2001年 | 34篇 |
2000年 | 27篇 |
1999年 | 21篇 |
1998年 | 24篇 |
1997年 | 17篇 |
1996年 | 18篇 |
1995年 | 13篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 12篇 |
1991年 | 16篇 |
1990年 | 16篇 |
1989年 | 20篇 |
1988年 | 22篇 |
1987年 | 13篇 |
1986年 | 16篇 |
1985年 | 12篇 |
1984年 | 4篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1976年 | 5篇 |
1974年 | 4篇 |
1973年 | 5篇 |
1972年 | 5篇 |
1969年 | 3篇 |
1967年 | 3篇 |
1965年 | 3篇 |
排序方式: 共有4061条查询结果,搜索用时 343 毫秒
111.
Drummond MF Becker DL Hux M Chancellor JV Duprat-Lomon I Kubin R Sagnier PP 《Chest》2003,124(2):526-535
STUDY OBJECTIVE: To evaluate costs, clinical consequences, and cost-effectiveness from a German and French health-care system perspective of sequential i.v./po moxifloxacin monotherapy compared to co-amoxiclav with or without clarithromycin (AMC +/- CLA) in patients with community-acquired pneumonia (CAP) who required parenteral treatment. METHODS: Costs and consequences over 21 days were evaluated based on clinical cure rates 5 to 7 days after treatment and health resource use reported for the TARGET multinational, prospective, randomized, open-label trial. This trial compared sequential i.v./po monotherapy with moxifloxacin (400 mg qd) to i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg bid) for 7 to 14 days in hospitalized patients with CAP. Since no country-by-treatment interaction was found in spite of some country differences for length of hospital stays, resource data (antimicrobial treatment, hospitalization, and out-of-hospital care) from all centers were pooled and valued using German and French unit prices to estimate CAP-related cost to the German Sickness Funds and French public health-care sector, respectively. RESULTS: Compared to AMC +/- CLA, treatment with moxifloxacin resulted in 5.3% more patients achieving clinical cure 5 to 7 days after therapy (95% confidence interval [CI], 1.2 to 11.8%), increased speed of response (1 day sooner for median time to first return to apyrexia, p = 0.008), and a reduction in hospital stay by 0.81 days (95% CI, - 0.01 to 1.63) within the 21-day time frame. Treatment with moxifloxacin resulted in savings of 266 euro and 381 euro for Germany and France respectively, primarily due to the shorter length of hospital stay. Cost-effectiveness acceptability curves show moxifloxacin has a > or = 95% chance of being cost saving from French and German health-care perspectives, and higher probability of being cost-effective at acceptability thresholds up to 2,000 euro per additional patient cured. CONCLUSION: i.v./po monotherapy with moxifloxacin shows clinical benefits including increased speed of response and is cost-effective compared to i.v./po AMC +/- CLA in the treatment of CAP. 相似文献
112.
113.
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells. The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of NHL during chronic HIV infection. To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS. In all 3 groups we observed a decline of EBV-specific memory CD4+ and CD8+ T-cell responses during HIV infection. However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors. Loss of EBNA1-specific T-cell immunity thus might be important for progression to NHL. Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells. 相似文献
114.
South Africa Every Death Counts Writing Group Bradshaw D Chopra M Kerber K Lawn JE Bamford L Moodley J Pattinson R Patrick M Stephen C Velaphi S 《Lancet》2008,371(9620):1294-1304
South Africa is one of the few developing countries with a national confidential inquiry into maternal deaths. 164 health facilities obtain audit data for stillbirths and neonatal deaths, and a new audit network does so for child deaths. Three separate reports have been published, providing valuable information about avoidable causes of death for mothers, babies, and children. These reports make health-system recommendations, many of which overlap and are intertwined with the scarcity of progress in addressing HIV/AIDS. The leaders of these three reports have united to prioritise actions to save the lives of South Africa's mothers, babies, and children. The country is off-track for the health-related Millennium Development Goals. Mortality in children younger than 5 years has increased, whereas maternal and neonatal mortality remain constant. This situation indicates the challenge of strengthening the health system because of high inequity and HIV/AIDS. Coverage of services is fairly high, but addressing the gaps in quality and equity is essential to increasing the number of lives saved. Consistent leadership and accountability to address crosscutting health system and equity issues, and to prevent mother-to-child transmission of HIV, would save tens of thousands of lives every year. Audit is powerful, but only if the data lead to action. 相似文献
115.
116.
117.
Background
The majority of patients with juvenile idiopathic arthritis (JIA) need specialized care when they enter adulthood. An increasing number of these patients take biologic disease modifying antirheumatic drugs (DMARDs) at the time of transition. The biologic register BiKeR provides information about the health status and healthcare situation of JIA patients during childhood and adolescence and with their entrance into adulthood these patients are systematically transferred to JuMBO, the follow-up register for young adults with JIA treated with biologics and nonbiologic DMARDs.Objective
The aim of this study was to investigate the healthcare situation of patients with JIA during transition from pediatric to adult care.Methods
The current analyses included patients who were successfully transferred from the BiKeR to JuMBO registers. The DMARD treatment and patient-reported outcome (i.e. disease activity, pain and functional ability) were assessed at the last documentation in BikeR and at the first as well as the last documentation in JuMBO.Results
During the transition period 1 in 10 JIA patients stopped DMARD therapy and 1 in 20 patients did not visit a physician for adults. Three-quarters of the adult JIA patients included in JuMBO (N?=?811) reached adult rheumatology care. Adult rheumatologists usually continued therapy with biologics in these patients. Every second patient was still being treated with etanercept, 5 years after the start of the first treatment with biologics. Adult rheumatologists changed the biologic substance in every fourth patient, mainly because of treatment failure. In comparison to patients in regular adult rheumatology care, those who did not remain in specialized care had a higher discontinuation rate of biologics. Moreover, patients with sporadic use of medical care had a significantly poorer health status than those with a regular use of medical care at least every 6 months.Conclusion
The data show that there is a need for improving healthcare during the period of transition from pediatric to adult rheumatology. 相似文献118.
Charlotte Bradbury Kate Fletcher Yongzhong Sun Carl Heneghan Chris Gardiner Andrea Roalfe Pollyanna Hardy Debbie McCahon Gail Heritage Helen Shackleford FD Richard Hobbs David Fitzmaurice 《British journal of haematology》2020,188(6):962-975
Venous thromboembolism (VTE) is prevalent and impactful, with a risk of death, morbidity and recurrence. Post-thrombotic syndrome (PTS) is a common consequence and associated with impaired quality of life (QoL). The ExACT study was a non-blinded, prospective, multicentred randomised controlled trial comparing extended versus limited duration anticoagulation following a first unprovoked VTE (proximal deep vein thrombosis or pulmonary embolism). Adults were eligible if they had completed ≥3 months anticoagulation (remaining anticoagulated). The primary outcome was time to first recurrent VTE from randomisation. The secondary outcomes included PTS severity, bleeding, QoL and D-dimers. Two-hundred and eighty-one patients were recruited, randomised and followed up for 24 months (mean age 63, male:female 2:1). There was a significant reduction in recurrent VTE for patients receiving extended anticoagulation [2·75 vs. 13·54 events/100 patient years, adjusted hazard ratio (aHR) 0·20 (95% confidence interval (CI): 0·09 to 0·46, P < 0·001)] with a non-significant increase in major bleeding [3·54 vs. 1·18 events/100 patient years, aHR 2·99 (95% CI: 0·81–11·05, P = 0·10)]. Outcomes of PTS and QoL were no different between groups. D-dimer results (on anticoagulation) did not predict VTE recurrence. In conclusion, extended anticoagulation reduced VTE recurrence but did not reduce PTS or improve QoL and was associated with a non-significant increase in bleeding. Results also suggest very limited clinical utility of D-dimer testing on anticoagulated patients. 相似文献
119.
120.